Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria

• •Ages 18 years and older
• •Diagnosis of CLL established by peripheral blood and bone marrow examination and using the standard criteria
• •Patients with Rai stage III or IV, or earlier stage with massive, symptomatic lymphadenopathy requiring therapy
• •Primary resistance to fludarabine-based therapy (no complete response \[CR\] or partial response \[PR\]) or progressive disease within 6 months of response to prior fludarabine containing regimen.
• •ECOG performance status of 0, 1, 2 or 3
• •Willing to take adequate contraception (i.e. latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study and 3 months after
• •All investigational treatments should have been discontinued for at least 1 week prior to the initiation of the study drug.